SCHEMBL1749084

SCHEMBL1749084

CCN(CC)C(c1ccnc2[nH]c(-c3cn(C)c4cc(OC)c(OC)cc34)cc12)S(=O)(=O)c1ccc(C)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.49
GSK3B P49841 2/20 0.38
JAK2 O60674 1/20 0.38
LCK P06239 1/20 0.38
GSK3A P49840 1/20 0.38
CDK7 P50613 1/20 0.38
BTK Q06187 1/20 0.38
LRRK2 Q5S007 1/20 0.38
AURKB Q96GD4 1/20 0.38
TP53 P04637 1/20 0.37
CDK9 P50750 11/20 0.36
CCNT1 O60563 10/20 0.36
KIT P10721 3/20 0.36
CLK1 P49759 1/20 0.35
CLK2 P49760 1/20 0.35
CLK3 P49761 1/20 0.35
DYRK1A Q13627 1/20 0.35
CLK4 Q9HAZ1 1/20 0.35
DYRK1B Q9Y463 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5797179 0.88 IGF1R (0.46) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL2634042 0.86 IGF1R (0.53) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1749096 0.84 IGF1R (0.51) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1748967 0.83 IGF1R (0.48) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1748812 0.82 IGF1R (0.49) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1748803 0.82 IGF1R (0.51) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1749209 0.82 IGF1R (0.49) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1749283 0.81 IGF1R (0.42) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL5793403 0.81 IGF1R (0.47) IGF1RGSK3BJAK2LCKGSK3A
SCHEMBL1748719 0.80 IGF1R (0.47) IGF1RGSK3BJAK2LCKGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885GSK3B 536/4885JAK2 42/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885GSK3B 536/4885JAK2 42/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.